GuoLine Advisory Pte Ltd Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• GuoLine Advisory Pte Ltd increased its stake in Regeneron Pharmaceuticals by 19.5%, owning 67,300 shares worth $35.3 million, making REGN the firm's 11th largest holding.
• Regeneron reported quarterly earnings of $12.89 EPS, significantly beating estimates of $8.43, with revenue of $3.68 billion, up 3.6% year-over-year.
• The company is currently valued at $59.35 billion and is seeing positive analyst sentiment, with an average target price of $817.67 and a "Moderate Buy" rating.

GuoLine Advisory Pte Ltd grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 19.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,300 shares of the biopharmaceutical company's stock after buying an additional 11,000 shares during the quarter. Regeneron Pharmaceuticals makes up 3.7% of GuoLine Advisory Pte Ltd's portfolio, making the stock its 11th biggest holding. GuoLine Advisory Pte Ltd owned 0.06% of Regeneron Pharmaceuticals worth $35,332,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Finally, Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $560.00 on Friday. The firm has a market capitalization of $59.35 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58. The business has a 50 day simple moving average of $564.61 and a 200-day simple moving average of $578.77. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the company earned $11.56 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

Several analysts recently issued reports on REGN shares. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research note on Wednesday, August 27th. Guggenheim increased their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Finally, Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.